Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of thrombotic risk between 85 homozygotes and 481 heterozygotes carriers of the factor V Leiden mutation: retrospective analysis from the Procare Study.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis - 1 Sept 2000

Abstract excerpt

Factor V Leiden is the most common risk factor in thrombophilia. However, whether homozygosity confers a higher risk than heterozygosity remains questionable. The first phase of the Procare Study was to collect clinical and biological data from individuals carrying the R506Q mutation. To date, 566 individuals have been included in 23 French centres. Data from 85 homozygotes were compared with those of 481...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age of Onset
Share to Factor V
Share to Family Health

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Incidence

Share to Prothrombin

Share to Pulmonary Embolism

Share to Recurrence

Share to Thrombosis

Source

Identifiers

PMID: 10997790
DOI: 10.1097/00001721-200009000-00002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of thrombotic risk between 85 homozygotes and 481 heterozygotes carriers of the factor V Leiden mutation: retrospective analysis from the Procare Study.PMID 10997790Read ↗

High risk of thrombosis recurrence in patients with homozygous and compound heterozygous factor V R506Q (Factor V Leiden) and prothrombin G20210ASemantic proximity Read ↗

High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)Semantic proximity Read ↗

Thrombosis in a patient with combined homozygosity for the factor V Leiden mutation and a mutation in the 3'-untranslated region of the prothrombin gene.Semantic proximity Read ↗

Impact of double heterozygosity for Factor V Leiden and Prothrombin G20210A on the thrombotic phenotype.Semantic proximity Read ↗

Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members.Semantic proximity Read ↗

Haplotypes of the EPCR gene, prothrombin levels, and the risk of venous thrombosis in carriers of the prothrombin G20210A mutation.Semantic proximity Read ↗

Prevalence of genetic prothrombotic risk factors: 1691G > A FV, 20210G > A PT and 677C > T MTHFR mutations in the Bosnian population.Semantic proximity Read ↗

The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease.Semantic proximity Read ↗

The impact of heterozygosity for the factor V Leiden and factor II G20210A mutations on the risk of thrombosis in Greek patients.Semantic proximity Read ↗

Do incident and recurrent venous thromboembolism risks truly differ between heterozygous and homozygous Factor V Leiden carriers? A retrospective cohort study.Semantic proximity Read ↗

Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank.Semantic proximity Read ↗

The prothrombin 20210 G to A variation and thrombosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.